I-Hui Chiang, MD
Interventional Cardiology · Mesa, AZNPI 1407065220
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Livanova USA, Inc. at 27.5% of the total. Reporting peaked in 2024 at $10,431 and has fallen 55.2% since, to $4,671 in 2025.
Across 218 payments — averaging $125.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$8K
- Abiomed$5K
- Shockwave Medical, Inc$3K
- Abbott$3K
- Penumbra, Inc.$2K
- Medtronic$1K
- plus $5K from 14 others
Across 2 payments — averaging $69,004 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Procyrion, Inc.$138K
What the payments were for
- Speaking & faculty fees$6,77325%
- Travel & lodging$7,08326%
- Food & beverage$13,51349%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 9 | $7,514 |
| Abiomed | 60 | $4,914 |
| Shockwave Medical, Inc | 39 | $3,398 |
| Abbott | 30 | $2,708 |
| Penumbra, Inc. | 8 | $2,499 |
| Medtronic | 13 | $1,224 |
| Medical Device Business Services, Inc. | 9 | $1,216 |
| Biosense Webster, Inc. | 10 | $1,049 |
| W. L. Gore & Associates, Inc. | 10 | $978 |
| Boston Scientific | 8 | $687 |
| Edwards Lifesciences | 3 | $310 |
| Atricure, Inc. | 1 | $183 |
| Inari Medical, Inc. | 1 | $172 |
| Bardy Diagnostics, Inc. | 6 | $145 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $140 |
| Heartflow, Inc. | 2 | $103 |
| Novartis | 3 | $62 |
| Cordis US CORP. | 2 | $33 |
| Amgen | 1 | $21 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeSPARC$7,498
- Impella$2,464
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$2,454
- Indigo System$2,335
- Carto 3$1,983
- AMPLATZER Occluders$1,184
- SYMPLICITY G3$793
- GORE CARDIOFORM ASD Occluder$465
- OPTIS$414
- AVVIGO Guidance System$379
- GORE CARDIOFORM Septal Occluder$259
- ATRICLIP LAA EXCLUSION SYSTEM$183
- AMPLATZER$174
- FLOWTRIEVER CATHETER, S$172
- CT THROMBECTOMY SYSTEM KIT$172
- MitraClip$140
- Legacy$140
- SAPIEN 3 Ultra RESILIA$136
- DRAGONFLY OPSTAR$135
- ENSITE PRECISION$131
How this compares
$27,368 in reported general payments places this provider in the 75th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 59 | $71,665 |
| EliquisApixaban | 38 | $47,302 |
| JardianceEmpagliflozin | 38 | $43,794 |
| FarxigaDapagliflozin Propanediol | 27 | $36,690 |
| Repatha SyringeEvolocumab | 14 | $21,621 |
| BrilintaTicagrelor | 23 | $18,743 |
| Metoprolol Succinate | 127 | $2,489 |
| Atorvastatin Calcium | 232 | $2,474 |
| Ezetimibe | 61 | $2,152 |
| Rosuvastatin Calcium | 100 | $1,908 |
| Carvedilol | 158 | $1,628 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 56 | $1,057 |
| Hydralazine Hcl | 55 | $998 |
| Nifedipine ErNifedipine | 31 | $935 |
| Lisinopril | 80 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $62 | $71,66559 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Mesa
- Faraj KargoliMesa$115K
- Nachiket PatelMesa$107K
- Satya Prakash AtmakuriMesa$41K
- Robert CandipanMesa$32K
- Paul SorajjaPhoenix$1.1M
- Hursh NaikAvondale$781K
- Thomas WaggonerTucson$617K
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
- Kapildeo LotunTucson$365K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.